ArticleBMC infectious diseases2025
Epidemiology and risk factors of fungal pathogens in sepsis: a prospective nationwide multicenter cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A Review of the Therapeutic Challenges and Novel Treatment Options in Mitigating Invasive Mycosis Associated withJournal of fungi (Basel, Switzerland) · 2026Review
- Genome mining reveals an architecturally expanded pyoluteorin-associated biosynthetic gene cluster and a divergent flavin-dependent halogenase-like sequence in deep-sea Pseudomonas Aeruginosa from the Gulf of Guinea.Antonie van Leeuwenhoek · 2026Article
- Clinical Characteristics of Carbapenem-Resistant Gram-Negative Bloodstream Infections and Fungemia Among High-Risk Pediatric Patients Receiving Empirical Antifungal Therapy.Pathogens (Basel, Switzerland) · 2026Observational
- Retrospective analysis of the epidemiological characteristics, risk factors, survival rate, and drug resistance of candidemia and construction of a logistic regression prediction model (2013-2024).BMC infectious diseases · 2026Article
- LAMP-Based Detection ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- How frailty index impacts death in chronic kidney disease: A retrospective observational investigation.PloS one · 2026Observational
- Dose-response relationship of pre-ICU corticosteroids and influenza-associated pulmonary aspergillosis: a multicenter target trial emulation.Annals of intensive care · 2026Article
- Reassessing sepsis research: new clues for old players and new players for an old symptom to improve patient outcomes.EXCLI journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe incidence of sepsis with identified fungal pathogens is increasing and is associated with higher morbidity and mortality. Co-infection with fungal infections in COVID-19 patients is attracting clinical attention. This study examines the epidemiology, risk factors, and outcomes among sepsis patients with identified fungal pathogens.
methodsWe conducted a nationwide cohort study of adult patients with sepsis from the Korean Sepsis Alliance Database in South Korea between September 2019 and December 2021. We identified 407 patients with documented fungal pathogens, categorized according to the presence of hemato-oncologic malignancies.
resultsOf the 11,981 patients with sepsis, fungal pathogens were identified in 3.4% of cases. Among these patients, 38.3% had co-existing hematologic or solid organ cancer. Older age, higher clinical frailty scale scores, and underlying conditions, such as chronic kidney disease, cerebrovascular disease, and dementia, were more prevalent in patients without hemato-oncologic malignancies. The most common fungal pathogens were Candida albicans (47.9%), Candida glabrata (20.6%), and Candida tropicalis (13.5%). Only 6.6% of the patients with confirmed fungal pathogens received antifungal treatment. The presence of hemato-oncologic malignancies did not significantly affect patient outcomes. Factors associated with the presence of identified fungal pathogens included chronic kidney disease (Odds ratio [OR] 1.662; 95% confidence interval [CI] 1.216-2.273; p = 0.001), connective tissue disease (OR 1.885; 95% CI 1.058-3.358; p = 0.032), immunocompromised status (OR 2.284; 95% CI 2.186-3.753; p = 0.001), and invasive mechanical ventilation (OR 2.864; 95% CI 2.186-3.753; p < 0.001).
conclusionsSepsis identified fungal pathogen are associated with chronic kidney disease, immunocompromised status and other risk factors, demonstrating the need for early detection, targeted management and improved antifungal strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.